Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Maternal genetic diseases: potential concerns for mother and baby.

Stone J, Reed D.

Hum Genet. 2019 Nov 15. doi: 10.1007/s00439-019-02086-6. [Epub ahead of print] Review.

PMID:
31729547
2.

Evaluating the Comparative Effectiveness of Two Diets in Pediatric Inflammatory Bowel Disease: A Study Protocol for a Series of N-of-1 Trials.

Kaplan HC, Opipari-Arrigan L, Schmid CH, Schuler CL, Saeed S, Braly KL, Burgis JC, Nguyen K, Pilley S, Stone J, Woodward G, Suskind DL.

Healthcare (Basel). 2019 Nov 1;7(4). pii: E129. doi: 10.3390/healthcare7040129.

3.

Replens prevents preterm birth by decreasing type I interferon strengthening the cervical epithelial barrier.

Nold C, Jensen T, O'Hara K, Stone J, Yellon SM, Vella AT.

Am J Reprod Immunol. 2019 Sep 24:e13192. doi: 10.1111/aji.13192. [Epub ahead of print]

PMID:
31549469
4.

Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson's disease to inform clinical trial designs.

Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit H, Weidemann J, Chen C, Yang M, Maciuca R, Lawson R, Burn D, Marek K, Venuto C, Stafford B, Akalu M, Stephenson D, Romero K; Critical Path for Parkinson's (CPP) Consortium.

Clin Pharmacol Ther. 2019 Sep 23. doi: 10.1002/cpt.1634. [Epub ahead of print]

PMID:
31544231
5.

Immunogenicity of pembrolizumab in patients with advanced tumors.

van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T.

J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4.

6.

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D.

Alzheimers Res Ther. 2019 Aug 7;11(1):68. doi: 10.1186/s13195-019-0520-1.

7.

Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.

Forman M, Palcza J, Tseng J, Stone JA, Walker B, Swearingen D, Troyer MD, Dockendorf MF.

Clin Transl Sci. 2019 Sep;12(5):545-555. doi: 10.1111/cts.12645. Epub 2019 Jun 19.

8.

Focus Issue Editorial: Biotic Stress.

Jin H, Mitchum M, Panstruga R, Stone J.

Plant Physiol. 2019 Apr;179(4):1193-1195. doi: 10.1104/pp.19.00330. No abstract available.

PMID:
30940733
9.

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.

Stone JA, McCrea JB, Witter R, Zajic S, Stoch SA.

Br J Clin Pharmacol. 2019 Jun;85(6):1072-1083. doi: 10.1111/bcp.13869. Epub 2019 Mar 18. Review.

PMID:
30663085
10.

Doubling: a model for international clinical partnerships.

Jureidini J, Stone J, Jureidini M.

Australas Psychiatry. 2019 Feb;27(1):41-43. doi: 10.1177/1039856218815760. Epub 2018 Nov 29.

PMID:
30488716
11.

Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.

Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M, Troyer MD, van Vugt M, Forman MS.

Clin Pharmacol Ther. 2019 May;105(5):1234-1243. doi: 10.1002/cpt.1258. Epub 2019 Jan 18.

PMID:
30347431
12.

Block of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Inflammation-Induced Preterm Birth in a Mouse Model for Parturition.

Nold C, Stone J, O'Hara K, Davis P, Kiveliyk V, Blanchard V, Yellon SM, Vella AT.

Reprod Sci. 2019 Apr;26(4):551-559. doi: 10.1177/1933719118804420. Epub 2018 Oct 8.

PMID:
30296925
13.

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.

Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA.

Clin Cancer Res. 2018 Dec 1;24(23):5841-5849. doi: 10.1158/1078-0432.CCR-18-0415. Epub 2018 Jun 11.

14.

Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP.

van Maanen EMT, van Steeg TJ, Ahsman MJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone J, Danhof M.

J Pharmacol Exp Ther. 2018 Jun;365(3):507-518. doi: 10.1124/jpet.117.244699. Epub 2018 Mar 21.

PMID:
29563326
15.

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.

Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K, Stephenson DT, Romero K; Critical Path for Parkinson's (CPP) Parkinson's Disease Modeling and Simulation Working Group.

Clin Transl Sci. 2018 Jan;11(1):63-70. doi: 10.1111/cts.12492. Epub 2017 Jul 27.

16.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.

Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y.

J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414. doi: 10.1007/s10928-017-9528-y. Epub 2017 Jun 1.

PMID:
28573468
17.

Evaluation of dosing strategy for pembrolizumab for oncology indications.

Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, Stone JA.

J Immunother Cancer. 2017 May 16;5:43. doi: 10.1186/s40425-017-0242-5. eCollection 2017.

18.

Is nitric oxide an essential mediator in cervical inflammation and preterm birth?

Nold C, Stone J, Graham M, Trinh J, Blanchette A, Jensen T.

J Matern Fetal Neonatal Med. 2018 Jul;31(13):1735-1741. doi: 10.1080/14767058.2017.1326898. Epub 2017 May 22.

PMID:
28475392
19.

Comparison of Self-reported and Measured Pre-pregnancy Weight: Implications for Gestational Weight Gain Counseling.

Bannon AL, Waring ME, Leung K, Masiero JV, Stone JM, Scannell EC, Moore Simas TA.

Matern Child Health J. 2017 Jul;21(7):1469-1478. doi: 10.1007/s10995-017-2266-3.

PMID:
28155023
20.

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.

Scott JD, Li SW, Brunskill AP, Chen X, Cox K, Cumming JN, Forman M, Gilbert EJ, Hodgson RA, Hyde LA, Jiang Q, Iserloh U, Kazakevich I, Kuvelkar R, Mei H, Meredith J, Misiaszek J, Orth P, Rossiter LM, Slater M, Stone J, Strickland CO, Voigt JH, Wang G, Wang H, Wu Y, Greenlee WJ, Parker EM, Kennedy ME, Stamford AW.

J Med Chem. 2016 Dec 8;59(23):10435-10450. Epub 2016 Nov 18.

PMID:
27933948

Supplemental Content

Loading ...
Support Center